Scientific article
Open access

Cyclin D1, cyclin E, and p21 have no apparent prognostic value in anal carcinomas treated by radiotherapy with or without chemotherapy

Published inBritish journal of cancer, vol. 91, no. 7, p. 1239-1244
Publication date2004

The purpose of this study was to assess the potential prognostic and/or predictive value of the expression of cyclin D1, cyclin E, and p21 protein in a series of 98 anal carcinomas (T1-4, N0-3) treated by radiotherapy with (51) or without (47) chemotherapy in one institution. Correlation with Mib1 index and p53 expression was also investigated. Median follow-up for surviving patients was 124 months (range: 30-266). Immunohistochemical staining was performed on pretreatment biopsies, applying a standard ABC technique for cyclin D1 (clone DSC6, DAKO, 1 : 300), cyclin E (clone 13A3, Novocastra, 1 : 100), p21(WAF/CIP1) (clone SX118, DAKO, 1 : 50), p53 (clone DO7, DAKO, 1 : 200), and Mib1 (Ki-67, Dianova, 1 : 20). Tumours were classified into low- or high-expression groups according to the expression level of the protein considered. High expression was found in 51% of tumours for cyclin E, in 33.7% for cyclin D1, and in 65% for p21. None of those factors were significantly associated with clinical variables such as advanced T or N categories. In a monovariate analysis, advanced T and N categories and longer overall treatment time were the only variables that correlated significantly with low rate of local control (LC) and disease-free survival. However, in a subgroup analysis, high p21 expression correlated with a trend for significantly higher 5-year LC (87 vs 68%, P=0.07) in the N0 patients. The results of this study suggest that the cell-cycle proteins investigated are unlikely to be clinically useful in predicting treatment response or prognosis in patients with anal carcinomas.

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Anus Neoplasms/drug therapy/pathology/radiotherapy
  • Carcinoma/drug therapy/pathology/radiotherapy
  • Cyclin D1/analysis
  • Cyclin E/analysis
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins/analysis
  • Disease-Free Survival
  • Enzyme Inhibitors/analysis
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Prognosis
  • Treatment Outcome
  • Tumor Markers, Biological/analysis
Citation (ISO format)
ALLAL, Abdelkarim Said, GERVAZ, Pascal, BRUNDLER, Marie-Anne. Cyclin D1, cyclin E, and p21 have no apparent prognostic value in anal carcinomas treated by radiotherapy with or without chemotherapy. In: British journal of cancer, 2004, vol. 91, n° 7, p. 1239–1244. doi: 10.1038/sj.bjc.6602111
Main files (1)
Article (Published version)
ISSN of the journal0007-0920

Technical informations

Creation09/23/2014 5:28:00 PM
First validation09/23/2014 5:28:00 PM
Update time03/14/2023 9:47:38 PM
Status update03/14/2023 9:47:37 PM
Last indexation01/16/2024 11:55:55 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack